Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ideation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    144 result(s) found for: Ideation. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2013-000970-31 Sponsor Protocol Number: TUD-ASLith-057 Start Date*: 2013-11-27
    Sponsor Name:Technische Universität Dresden
    Full Title: Randomized, placebo-controlled multicenter trial of lithium plus treatment as usual (TAU) for acute suicidal ideation and behaviour in patients with suicidal major depressive episode
    Medical condition: Diagnosis of a major depressive episode; inpatient at screening visit; suicidal ideation/behaviour present defined by a clinical rating of ≥ 8 on the Sheehan Suicidality Tracking Scale (S-STS) at...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10012397 Depression suicidal PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-003816-38 Sponsor Protocol Number: PHRC-N/2017-FJ-01 Start Date*: 2020-11-09
    Sponsor Name:CHU DE NIMES
    Full Title: Add-on buprenorphine at analgesic doses for the treatment of severe suicidal ideas during a major depressive episode
    Medical condition: Treatment of severe suicidal ideas in patients suffers from a current major depressive episode
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10083288 Clinical depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-004422-42 Sponsor Protocol Number: ESKETINSUI2002 Start Date*: 2017-10-02
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-blind, Randomized, Psychoactive Placebo-controlled, Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (28 mg, 56 mg and 84 mg) of Intranasal Esketamine in Addition to Comprehensiv...
    Medical condition: Major Depressive Disorder with Imminent Risk of Suicide
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10042458 Suicidal ideation PT
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012397 Depression suicidal PT
    20.0 10037175 - Psychiatric disorders 10065604 Suicidal behaviour PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) ES (Restarted) BE (Completed) PL (Completed) IT (Completed) BG (Completed) FR (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-003992-23 Sponsor Protocol Number: 54135419SUI3002 Start Date*: 2017-07-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Sympto...
    Medical condition: Major Depressive Disorder with Imminent Risk of Suicide
    Disease: Version SOC Term Classification Code Term Level
    20.1 10037175 - Psychiatric disorders 10042458 Suicidal ideation PT
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012397 Depression suicidal PT
    20.0 10037175 - Psychiatric disorders 10065604 Suicidal behaviour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) CZ (Completed) AT (Completed) LT (Completed) FR (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-003720-16 Sponsor Protocol Number: CMIJ821A12201 Start Date*: 2021-10-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A double-blind, placebo-controlled, randomized dose-ranging trial to investigate efficacy and safety of intravenous MIJ821 infusion in addition to comprehensive standard of care on the rapid reduct...
    Medical condition: Major Depressive Disorder with suicidal ideation with intent
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SK (Prematurely Ended) NL (Prematurely Ended) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003990-17 Sponsor Protocol Number: 54135419SUI3001 Start Date*: 2017-05-18
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Sympto...
    Medical condition: Major Depressive Disorder with Imminent Risk of Suicide
    Disease: Version SOC Term Classification Code Term Level
    20.1 10037175 - Psychiatric disorders 10042458 Suicidal ideation PT
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    20.0 10037175 - Psychiatric disorders 10012397 Depression suicidal PT
    20.0 10037175 - Psychiatric disorders 10065604 Suicidal behaviour PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) HU (Completed) ES (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-004745-70 Sponsor Protocol Number: 55438 Start Date*: 2018-11-06
    Sponsor Name:Academic Medical Center (AMC)
    Full Title: Efficacy of intranasal ketamine on acute suicidality, a double blind randomized placebo-controlled trial (Ketamine Trial Amsterdam, KETA)
    Medical condition: Acute suicidality, which is a rapid increase in suicidal ideation or behaviour from the patient's 'baseline' in the last 24 hours.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002905-24 Sponsor Protocol Number: 74304 Start Date*: 2021-07-07
    Sponsor Name:University Medical Center Groningen
    Full Title: Efficacy and feasibility of intranasal ketamine on acute suicidality, a double blind randomized placebo-controlled trial (Ketamine Trial for Acute suicidalty, KETA)
    Medical condition: Acute suicidality, which is a rapid increase in suicidal ideation or behaviour from the patient's 'baseline' in the last 24 hours.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001556-21 Sponsor Protocol Number: SEP361-202 Start Date*: 2016-10-27
    Sponsor Name:SUNOVION PHARMACEUTICALS INC.
    Full Title: A 26-Week Open-label Safety and Tolerability Extension Study of SEP-363856 in Adult Subjects with Schizophrenia
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2017-000211-16 Sponsor Protocol Number: F1J-MC-HMFN Start Date*: 2017-03-02
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: F1J-MC-HMFN (a) An Open-Label Study of Tolerability, Safety, and Pharmacokinetics of Duloxetine in the Treatment of Children and Adolescents With Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001555-41 Sponsor Protocol Number: SEP361-201 Start Date*: 2016-10-27
    Sponsor Name:SUNOVION PHARMACEUTICALS INC.
    Full Title: A 4-Week, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexibly-dosed, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Adult Subjects With ...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10037175 - Psychiatric disorders 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2020-002787-32 Sponsor Protocol Number: RG_19-172 Start Date*: 2020-11-16
    Sponsor Name:University of Birmingham
    Full Title: Antidepressant for the prevention of DEPression following first episode Psychosis trial
    Medical condition: Patients with First Episode Psychosis.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-004984-31 Sponsor Protocol Number: DR180133 Start Date*: 2021-04-21
    Sponsor Name:CHRU TOURS
    Full Title: Nitrous Oxide in Resistant Depression in Elderly Subjects: A Randomized, Double-blind, Comparator Trial
    Medical condition: Resistant Depression in the Elderly Subject
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002470-27 Sponsor Protocol Number: 3101-312-002 Start Date*: 2021-05-12
    Sponsor Name:Allergan Limited
    Full Title: A PHASE 3, MULTICENTER, OPEN-LABEL 52-WEEK EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ORAL ATOGEPANT FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH CHRONIC OR EPISODI...
    Medical condition: Chronic or Episodic Migraine (Migraine without aura, migraine with aura, or chronic migraine)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10027603 Migraine headaches HLT
    20.0 10029205 - Nervous system disorders 10027599 Migraine PT
    21.1 10029205 - Nervous system disorders 10066636 Chronic migraine LLT
    22.0 10029205 - Nervous system disorders 10082019 Episodic migraine LLT
    20.0 10029205 - Nervous system disorders 10052787 Migraine without aura PT
    20.0 10029205 - Nervous system disorders 10027607 Migraine with aura PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) SE (Completed) HU (Trial now transitioned) DK (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-001598-18 Sponsor Protocol Number: F1J‐MC‐HMCL Start Date*: 2017-05-09
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Major Depressive Disorder
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-004681-33 Sponsor Protocol Number: D1447C00001 Start Date*: 2005-04-15
    Sponsor Name:AstraZeneca AB
    Full Title: An International, Multi-centre, Double-blind, Randomised, Parallel-group, Placebo-controlled, Phase III study of the Efficacy and Safety of Quetiapine Fumarate (Seroquel™, single oral 300 mg or 600...
    Medical condition: Bipolar Depression
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) EE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000688-22 Sponsor Protocol Number: 750203.01.002 Start Date*: 2020-10-16
    Sponsor Name:Dr. Willmar Schwabe GmbH & Co. KG
    Full Title: Multi-centre, double-blind, placebo- and reference-controlled, randomised trial to prove the efficacy and safety of Silexan (WS®1265) in patients with a major depressive episode of mild to moderate...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10083288 Clinical depression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-004235-23 Sponsor Protocol Number: M15-737 Start Date*: 2020-11-09
    Sponsor Name:Abbvie Deutschland GmbH & Co. KG
    Full Title: An open-label extension of Study M15-741 to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease.
    Medical condition: Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) GB (GB - no longer in EU/EEA) DK (Completed) IT (Completed) DE (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000870-29 Sponsor Protocol Number: RISSCH3001 Start Date*: 2004-11-04
    Sponsor Name:Janssen-Cilag Medical Affairs EMEA
    Full Title: CONSTATRE Risperdal Consta Trial of Relapse Prevention and Effectiveness
    Medical condition: SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) AT (Completed) SE (Completed) CZ (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-001991-32 Sponsor Protocol Number: BN42489 Start Date*: 2023-01-13
    Sponsor Name:F.Hoffmann-La Roche Ltd
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, BIOMARKERS, AND EFFICACY OF TOMINERSEN IN INDIVIDUALS WITH PRODROMAL AND EARLY MANIFEST HUNTINGT...
    Medical condition: Huntington's disease (HD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) DE (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 14:52:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA